Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Cariporide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.63 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cariporide SCHEMBL6261845 | 1.00 | SLC9A1 (0.63) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL39639 | 0.99 | SLC9A1 (0.61) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL1229789 | 0.97 | SLC9A1 (0.60) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL220085 | 0.97 | SLC9A1 (0.60) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Hydrochloric Acid SCHEMBL8816752 | 0.87 | SLC9A1 (0.47) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| SCHEMBL8743805 | 0.86 | SLC9A1 (0.47) | SLC9A1SLC9A2PLAUCA1CA2 | |
| Hydrochloric Acid SCHEMBL8983516 | 0.85 | SLC9A1 (0.46) | SLC9A1SLC9A2PLAUCA1CA2 | |
| Hydrochloric Acid SCHEMBL8743814 | 0.85 | SLC9A1 (0.46) | SLC9A1SLC9A2PLAUCA1CA2 | |
| SCHEMBL8647598 | 0.84 | SLC9A1 (0.44) | SLC9A1SLC9A2CNR2PLAUCA1 | |
| Cariporide SCHEMBL936191 | 0.83 | ALDH1A1 (0.48) | SLC9A1SLC9A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005079803-A1 | COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASES | PFIZER PRODUCTS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-6770678-B1 | Lyophilisates having improved reconstitutability | MERCK PATENT GMBH (DE) | 2004-08-03 | — | — | US | claimed |
| EP-1146863-B1 | LYOPHILISATES WITH IMPROVED RECONSTITUTIBILITY | MERCK PATENT GMBH (DE) | 2004-05-12 | — | — | EP | claimed |
| CN-1367689-A | Use of sodium-hydrogen exchanger inhibitors for producing medicaments for preventing organ dysfunction and diseases caused by aging and for prolonging life | AVENTIS PHARMA GMBH (DE) | 2002-09-04 | — | — | CN | claimed |
| US-6420430-B1 | USE OF BENZOYLGUANIDINE DERIVATIVES TO PREVENT AGING DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-16 | — | — | US | claimed |
| EP-0589336-B1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AG (DE) | 1997-01-08 | — | — | EP | claimed |
| US-5591754-A | Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-07 | — | — | US | claimed |
| US-8530516-B2 | Promoting cycling of ApoE4 isoform | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-10 | — | — | US | disclosed |
| US-8088799-B2 | E.g., combination of cariporide and ramipril for preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-20090143473-A1 | USE OF INHIBITORS OF THE CELLULAR NA+/H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| CN-1319528-C | Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for | AVENTIS PHARMA GMBH (DE) | 2007-06-06 | — | — | CN | disclosed |
| US-20050261164-A1 | Remedy for urinary frequency and urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| CN-1694697-A | Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for | AVENTIS PHARMA GMBH (DE) | 2005-11-09 | — | — | CN | disclosed |
| US-20040122096-A1 | Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids | HOECHST AKTIENGESELLSCHAFT | 2004-06-24 | — | — | US | disclosed |
| US-20030158247-A1 | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
| WO-2003039528-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOSINE A1/A2 AGONIST AND A SODIUM HYDROGEN EXCHANGER INHIBITOR | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6462024-B1 | ARYL OR HETEROCYCLIC CARBONOYLGUANIDINES; PROTECTING ENDANGERED HEART TISSUE FROM DAMAGE FROM CARDIOTOXICS, SUCH AS SNAKE VENOMS OR FISH, MARINE JELLYFISH STING, SPIDER OR SCORPION TOXINS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-0937459-A2 | Pharmaceutical compositions for the treatment of ischemic brain damage | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
| CN-1209995-A | Use of sodium-hydrogen exchanger inhibitors for the production of a medicament for reducing the adverse effects of substances on the heart | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-03-10 | — | — | CN | disclosed |
| US-5591754-A | Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261164-A1 | Remedy for urinary frequency and urinary incontinence | SLC14A1, SLC26A4, SLC6A12 | SLC9A1 39/4885SLC9A2 50/4885CNR2 2502/4885 |
| US-20040122096-A1 | Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids | NHERF1, SLC8B1, LIPG | SLC9A1 7/4885SLC9A2 8/4885CNR2 2607/4885 |
| US-20090143473-A1 | USE OF INHIBITORS OF THE CELLULAR NA+/H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS | NHERF1, LIPG, SLC8B1 | SLC9A1 8/4885SLC9A2 13/4885CNR2 2567/4885 |
| US-20030158247-A1 | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | ACE, REN, ACE2 | SLC9A1 4/4885SLC9A2 8/4885CNR2 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.